LONDON , March 4 (Reuters) - GlaxoSmithKline Plc's (GSK.L: Quote, Profile , Research)(GSK.N: Quote, Profile , Research) claim to have one of the best new drug pipelines in the industry has suffered a setback with the loss of a number of experimental medicines in mid-stage clinical testing.
